Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Operating Margin (2022 - 2025)

ARS Pharmaceuticals' Operating Margin history spans 4 years, with the latest figure at 147.63% for Q4 2025.

  • For Q4 2025, Operating Margin fell 20771.0% year-over-year to 147.63%; the TTM value through Dec 2025 reached 212.92%, down 21488.0%, while the annual FY2025 figure was 212.92%, 21488.0% down from the prior year.
  • Operating Margin for Q4 2025 was 147.63% at ARS Pharmaceuticals, up from 163.66% in the prior quarter.
  • Across five years, Operating Margin topped out at 60.08% in Q4 2024 and bottomed at 206030.0% in Q2 2023.
  • The 4-year median for Operating Margin is 1061.19% (2024), against an average of 25890.08%.
  • The largest annual shift saw Operating Margin plummeted -20466276bps in 2023 before it skyrocketed 20296200bps in 2024.
  • A 4-year view of Operating Margin shows it stood at 3507.94% in 2022, then crashed by -5773bps to 206030.0% in 2023, then skyrocketed by 100bps to 60.08% in 2024, then plummeted by -346bps to 147.63% in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Operating Margin are 147.63% (Q4 2025), 163.66% (Q3 2025), and 302.95% (Q2 2025).